Libra Infusions (DHA:LIBRAINFU) Operating Income: BDT Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:LIBRAINFU Libra Infusions Ltd DHA:LIBRAINFU
21 GF Score
Price BDT636.10
View Full Analysis

What is Libra Infusions Operating Income?

Libra Infusions DHA:LIBRAINFU -0.16% 21 Operating Income is BDT Mil as of . 20. GuruFocus rates DHA:LIBRAINFU with a GF Score™ of 21/100.

Libra Infusions's Operating Income for the six months ended in . 20 was BDT0.00 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Libra Infusions's Operating Income for the six months ended in . 20 was BDT0.00 Mil. Libra Infusions's Revenue for the six months ended in . 20 was BDT0.00 Mil. Therefore, Libra Infusions's Operating Margin % for the quarter that ended in . 20 was %.

Libra Infusions's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Libra Infusions  (DHA:LIBRAINFU) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Libra Infusions's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is one times the annual (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Libra Infusions's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Libra Infusions's Operating Margin % for the quarter that ended in . 20 is calculated as:

Operating Margin %=Operating Income (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Libra Infusions Operating Income Related Terms

Libra Infusions Operating Income Historical Data

* Premium members only.

The historical data trend for Libra Infusions's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Libra Infusions Operating Income Chart

Libra Infusions Annual Data
Trend
Operating Income

Libra Infusions Semi-Annual Data
Operating Income
DHA:LIBRAINFU
21GF Score
Libra Infusions Ltd DHA:LIBRAINFU
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Libra Infusions Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Operating Income for the trailing twelve months (TTM) ended in . 20 was BDT Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of BDT Mil mean?
Libra Infusions (DHA:LIBRAINFU) has a Operating Income of BDT Mil as of . 20. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Libra Infusions and its competitors.
Is Libra Infusions' Operating Income too high?
Libra Infusions' current Operating Income is BDT Mil. Overall, Libra Infusions has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Libra Infusions' Operating Income compare to SECI and LENSF?
Libra Infusions' Operating Income of BDT Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Devices & Instruments company?
A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Libra Infusions and its competitors. Libra Infusions's current Operating Income is BDT Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Libra Infusions stock overvalued right now?
Libra Infusions (DHA:LIBRAINFU) has a current Operating Income of BDT Mil. The current Operating Income is BDT Mil. Libra Infusions' overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Libra Infusions (DHA:LIBRAINFU), the current Operating Income is BDT Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Libra Infusions Business Description

Address I/7, Mirpur Industrial Estate, Rupnagar, Section-2, Dhaka, BGD, 1216
Libra Infusions Ltd is engaged in manufacturing intravenous fluids. It provides products which are used for medical purposes involving surgical operations, loss of blood, weakness, and general hospitalization.
21GF Score

Get the complete analysis for DHA:LIBRAINFU

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT636.10
Price